Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.69 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12716746 | 0.93 | PPARG (0.60) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL10589345 | 0.92 | PPARG (0.59) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL29032842 | 0.91 | PPARG (0.58) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Hydrochloric Acid SCHEMBL524 | 0.91 | PPARG (0.58) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL13616765 | 0.90 | PPARG (0.59) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL21083962 | 0.89 | AGTR1 (0.64) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL688 | 0.89 | PPARG (0.56) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL7177667 | 0.89 | AGTR1 (0.63) | AGTR1AGTR2 | |
| SCHEMBL397 | 0.89 | PPARG (0.58) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL12716740 | 0.88 | PPARG (0.61) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114705764-A | Method for detecting content of losartan impurity | 浙江美诺华药物化学有限公司 | 2022-07-05 | — | — | CN | claimed |
| CN-114539227-A | Preparation method of losartan | 浙江美诺华药物化学有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-114705764-B | Method for detecting content of losartan impurity | 浙江美诺华药物化学有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2023181045-A1 | PROCESS FOR THE PREPARATION OF CARCINOGENIC AZIDO IMPURITIES FREE LOSARTAN AND SALTS THEREOF | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-09-28 | — | — | WO | disclosed |
| CN-116606282-A | Process for the preparation of losartan potassium and intermediates related thereto | 杭州新曦科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2023116514-A1 | HIGH-PURITY LOSARTAN POTASSIUM AND PREPARATION METHOD THEREFOR | 浙江华海药业股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116515-A1 | METHOD FOR PREPARING HIGH-PURITY LOSARTAN | 浙江华海药业股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | HETERO LABS LIMITED (IN) | 2023-05-23 | — | — | US | disclosed |
| US-20230046186-A1 | Process for the preparation of angiotensin receptor blockers or pharmaceutically acceptable salts thereof | Jubilant Pharma Holdings Inc. (US) | 2023-02-16 | — | — | US | disclosed |
| WO-2023007502-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN RECEPTOR BLOCKERS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Jubilant Generics Limited (IN) | 2023-02-02 | — | — | WO | disclosed |
| US-20220388988-A1 | Preparation Method For Losartan | ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| US-4874867-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| US-4870186-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
| US-4820843-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0291969-A2 | Tetrazole intermediates to antihypertensive compounds | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | disclosed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388988-A1 | Preparation Method For Losartan | AGTR1, AGT, AGTR2 | AGTR1 1/4885AGTR2 3/4885ABCC4 2229/4885 |
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | AGTR2, AGTR1, ADRB1 | AGTR1 2/4885AGTR2 1/4885ABCC4 2668/4885 |
| US-20230046186-A1 | Process for the preparation of angiotensin receptor blockers or pharmaceutically acceptable salts thereof | AGTR1, AGTR2, ADRB1 | AGTR1 1/4885AGTR2 2/4885ABCC4 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.